More Information: Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-MM-2: Human Multiple Myeloma Cell Line

SK1989-002

Description

SK-MM-2 is a multiple myeloma cell line that grows in suspension culture. These cells display plasmacytoid morphology and have a doubling time of approximately 60 hours. SK-MM-2 cells do not express the Epstein-Barr virus nuclear antigen. These cells express the pan-B-cell marker B1 and the late B-cell/plasma cell markers BL3, OKT10, and PCA-1, but do not express any T-lymphocyte, myeloid, or early B-lymphocyte markers. These cells secrete kappa light chains, but do not secrete any heavy chains. In addition, SK-MM-2 cells also express elevated levels of Cyclin D1 mRNA.

Source

This cell line was established in 1982, from a leukapheresis sample of peripheral blood, from a 54-year-old male, of unknown ethnicity, with plasma cell leukemia.

Inventors

Alan N. Houghton, MD, Attending Physician, Department of Medicine, Memorial Hospital; and Member, Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Eton O et al. (1989) Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3: 729-735 (PubMed ID: 2506399)
  • Sáez B et al. (2007) Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes. Cancer Genetics and Cytogenetics 175: 65-68 (PubMed ID: 17498561)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications